Portage Biotech Inc ( (PRTG) ) just unveiled an announcement.
On March 12, 2025, Portage Biotech Inc. announced the resumption of patient enrollment in the final cohort of the dose escalation stage for PORT-6 in the ADPORT-601 trial, following a pause due to funding concerns. This move highlights the promising safety profile observed in earlier cohorts and the company’s confidence in the therapeutic potential of PORT-6. The trial’s progression is a significant step towards determining an optimal dose range for further clinical development. Additionally, Portage is preparing for the co-administration of PORT-6 and PORT-7, marking a pioneering approach in combining selective A2A and A2B antagonists to combat adenosine-induced immunosuppression in tumors, potentially broadening the impact of immunotherapy.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company focused on developing a pipeline of novel biologics to enhance the immune system’s ability to fight cancer. The company is engaged in advancing innovative therapeutics, particularly selective A2A and A2B antagonists, aimed at improving immunotherapy outcomes in solid tumors.
YTD Price Performance: -14.55%
Average Trading Volume: 725,459
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.67M
For an in-depth examination of PRTG stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com